Novel RIPTAC molecule shows promising activity in heavily pretreated mCRPC
Johnson & Johnson's JNJ-6143, a first-in-class oral RIPTAC molecule, showed promising activity in heavily pretreated mCRPC patients, according to phase 1 data presented at ESMO 2026. At 50 mg daily, 77% of patients achieved a PSA decline of at least 50%, and 48% saw a 90% decline. The drug demonstrated a favorable safety profile, with a phase 2 study now initiated.
How this was made
The 30-second read
Why it matters
The data suggest a potentially transformative therapy, prompting analyst upgrades and speculative buying.
Market read
First disclosure of strong phase‑1 results for a novel oncology platform, likely to move JNJ stock and affect biotech sentiment.
What to watch
Safety signals remain limited; long‑term toxicity and regulatory hurdles could temper upside.
Background
Johnson & Johnson presented first‑in‑human oral RIPTAC JNJ‑6143 data at the 2026 ESMO Congress, targeting androgen‑receptor and BRD4 in prostate cancer.
Ticker impact
Phase 1 data for JNJ-6143 in mCRPC shows 77% PSA50 response and 69% ORR, a first‑time disclosure.
upward pressure as market prices in encouraging efficacy and safety data
First report of strong efficacy signals in a high‑need cancer indication; investors typically reward such breakthroughs.
Market effects
May boost biotech and oncology sectors, especially firms developing RIPTAC or AR‑targeted therapies.
Limited to US markets where JNJ trades; modest ripple to European biotech peers.
Highlights emerging oral RIPTAC platform, could influence global R&D pipelines.
Counterpoint
Phase 1 data are early; efficacy may not translate to later stages, risk of over‑optimism.
Key entities
- companyJohnson & Johnson
Developer of JNJ‑6143, listed on NYSE under ticker JNJ.
- personBenjamin Garmezy, MD
Presenting author and lead investigator of the trial.
